MultiOmic Health Secures $6.2 Million Funding Boost

MultiOmic Health, a pioneering AI-enabled drug discovery company, has recently secured a significant funding boost of $6.2 million to fuel its mission of revolutionising precision medicine for metabolic syndrome-related conditions. Led by Hoxton Ventures, along with Ada Ventures, MMC Ventures, and Verve Ventures, this investment underscores the urgency and potential of addressing the complex challenges posed by metabolic disorders.

‍

Metabolic syndrome, characterized by a cluster of risk factors including high blood sugar, excess weight, hypertension, and abnormal lipid levels, affects a staggering one in three adults globally. The repercussions are dire, leading to debilitating conditions such as type 2 diabetes, chronic kidney disease, cardiovascular issues, and more. Despite its widespread impact, current treatment options often fall short, merely mitigating risks rather than targeting the root causes with precision.

‍

Robert Thong, Co-Founder and CEO of MultiOmic Health, highlights the inadequacy of existing treatments, noting that they fail to address the diverse array of disease variants stemming from genetics, lifestyle, and environmental factors. Unlike cancer, which has benefited from targeted therapies, metabolic disorders lack tailored precision medicines. MultiOmic aims to fill this void by leveraging advanced AI algorithms to decipher the intricate molecular drivers behind each disease variant.

‍

Thong emphasizes the importance of a patient-centric approach, where treatments are derived directly from comprehensive patient data rather than traditional laboratory experiments. This shift from "bench to bedside" to "bedside to lab bench" represents a paradigmatic change in drug discovery, promising more effective and personalised therapies for individuals battling metabolic syndrome-related conditions.

‍

The funding will propel MultiOmic's innovative MOHSAIC® platform, which integrates machine learning, systems biology simulations, and targeted wet lab experiments. By analysing complex multi-omics data alongside clinical information, MOHSAIC® identifies unique treatment concepts tailored to individual patients, offering hope for more effective interventions.

‍

Alasdair Thong, Co-Founder and Non-Executive Director of MultiOmic, underscores the transformative potential of AI and data science in addressing metabolic disorders. With declining omics data costs and rapid advancements in AI technologies, the time is ripe to harness these tools for the benefit of patients worldwide.

The focus of MultiOmic's initial efforts will be on diabetic kidney disease, a complication affecting a significant portion of diabetic individuals and contributing substantially to global healthcare costs. By demonstrating proof-of-concept in this critical area, MultiOmic aims to pave the way for broader applications across the spectrum of metabolic syndrome-related conditions.

‍

Investors, including Hoxton Ventures and Ada Ventures, recognise the urgent need for innovative solutions in addressing metabolic disorders. Rob Kniaz, Partner at Hoxton Ventures, highlights the transformative potential of technology in tackling unmet medical needs, particularly in the wake of the COVID-19 pandemic, which has exacerbated the risk factors associated with metabolic syndrome.

‍

As MultiOmic Health embarks on its mission to unlock the mysteries of metabolic disorders, it represents a beacon of hope for millions worldwide. Through its pioneering approach and relentless commitment to precision medicine, MultiOmic aims to rewrite the narrative for individuals grappling with metabolic syndrome-related conditions, offering new pathways to health and wellbeing in an increasingly complex medical landscape.

‍